West Pharmaceutical Services, Inc. WST
Composite 57/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 16/100 — a strong mark against it.
Balance-sheet strength ranks 83/100 — a strong point in its favour. Momentum ranks 70/100 — a moderate point in its favour. Quality ranks 68/100 — a moderate point in its favour.
Valuation ranks 16/100 — a strong mark against it. Income ranks 35/100 — a moderate mark against it.
What the company does West Pharmaceutical Services designs and makes containment and delivery systems for injectable drugs and healthcare products. Its Proprietary Products segment supplies stoppers, seals, syringe components, cartridges, films, coatings, and self-injection devices, while the Contract-Manufactured Products segment provides packaging and components. The company serves biologic, generic, and pharmaceutical drug makers globally.
Key financials Revenue grew 6% and EPS grew 2% year-over-year. Gross, operating, and net margins are 37%, 23%, and 17%, respectively. ROE is 19% and ROA is 11%. Debt/equity is 0.11 with net debt/EBITDA at -0.13 and a current ratio of 2.82.
Stock health Momentum scores are mixed: 3-month +5%, 6-month +33%, 12-month +38%, and -13% from the 52-week high. RSI(14) is 39, indicating neutral momentum. SideraVista scores Quality 69, Growth 55, Strength 84, Valuation 17, Momentum 69, and Income 35.
Price vs fair value The stock trades at a discount of 19.90% versus the analyst mean target of 404.73. - Forward P/E of 40x and PEG of 3.6x are rich versus peers (Valuation 17/100). - Recent biopharma partnerships and regulatory approvals cited in news may support long-term growth (Zacks, StockStory). - Analysts remain cautiously optimistic, with mixed price targets and limited near-term upside (Barchart).
Looking forward Forward P/E of 40x implies high expectations for margin stability and growth. Revenue and EPS growth of 6% and 2% respectively may challenge valuation unless execution accelerates. Watch for updates on proprietary product launches and contract wins.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.